Profil
Jean-François Le Bigot is currently the Chief Executive Officer at Oncovita SAS and the Chairman at Ginko Invest.
He was previously the Director at Affluent Medical SA from 2020 to 2022.
Aktive Positionen von Jean-François Le Bigot
| Unternehmen | Position | Beginn |
|---|---|---|
Oncovita
 Oncovita BiotechnologyHealth Technology Oncovita SAS is a biotech company based in Paris, France. Oncovita is developing a virus-derived vaccine technology to treat multiple types of cancers. The technology utilizes the natural anti-cancer and immunogenic properties of a harmless vaccine, making it a versatile platform. The MeasovirTM platform, derived from the safe and highly immunogenic measles vaccine virus, has clinically proven oncolytic potential and specifically targets and destroys cancer cells. The French company was founded in 2015 by Frédéric Tangy and is currently led by CEO Jean-François Le Bigot. | Vorstandsvorsitzender | - |
Ginko Invest
 Ginko Invest Financial ConglomeratesFinance Ginko Invest operates as an investment firm. | Vorsitzender | - |
Ehemalige bekannte Positionen von Jean-François Le Bigot
| Unternehmen | Position | Ende |
|---|---|---|
| AFFLUENT MEDICAL | Direktor/Vorstandsmitglied | 19.01.2022 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AFFLUENT MEDICAL | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Oncovita
Oncovita BiotechnologyHealth Technology Oncovita SAS is a biotech company based in Paris, France. Oncovita is developing a virus-derived vaccine technology to treat multiple types of cancers. The technology utilizes the natural anti-cancer and immunogenic properties of a harmless vaccine, making it a versatile platform. The MeasovirTM platform, derived from the safe and highly immunogenic measles vaccine virus, has clinically proven oncolytic potential and specifically targets and destroys cancer cells. The French company was founded in 2015 by Frédéric Tangy and is currently led by CEO Jean-François Le Bigot. | Health Technology |
Ginko Invest
Ginko Invest Financial ConglomeratesFinance Ginko Invest operates as an investment firm. | Finance |
